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Clinical relevance of stroke
According  to  the  definition  of  the  World  Health 
Organization, stroke is defined as suddenly developing, 
temporary or, in unfavorable cases, permanent damage to 
the brain [1,2]. It can affect both men and women at any 
time of life; however, it is more prevalent in men over 45 
years of age [3].
The  disease  can  be  classified  into  two  subgroups: 
hemorrhagic  stroke,  involving  leakage  of  blood,  and 
ischemic stroke, involving blockage of blood flow. Ischemic 
stroke comprises 80 to 85% of all stroke cases; 15 to 20% 
of  the  cases  are  hemorrhagic,  which  comprise  intra­
cerebral and subarachnoid stroke. Ischemic stroke can be 
the  result  of  various  pathophysiological  mechanisms, 
such  as  atherothrombosis  (75%  of  cases)  or  embolism 
(25% of cases), which lead to occlusions in the arteries. 
However, up to 30% of ischemic strokes can have other 
causes, such as systemic hypoperfusion (general decrease 
in blood circulation).
Acute  ischemic  stroke  has  been  listed  as  the  third 
leading cause of mortality after cardiovascular events and 
malignant tumors [4,5]. However, the number of stroke 
attacks is on the rise owing to demographic changes and 
inadequate primary or secondary prevention [6]. Donnan 
et al. [7] regarded stroke as the second most common 
cause of death after ischemic heart disease worldwide.
The incidence, prevalence and mortality of stroke show 
huge  differences  from  one  country  to  another.  The 
incidence rates of stroke in the USA are the highest in the 
world,  with  780,000  cases  annually;  150,000  deaths 
occurred in 2004. Its prevalence was approximately 5.8 
million,  of  which  87%  was  ischemic  stroke  [8].  The 
incidence of stroke is smaller in European populations 
than in the USA, with large geographical variations in 
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eastern to western European countries [9].
The strict classification of ischemic stroke into subtypes 
is crucial if we are to understand its etiology. It can be 
divided  into  three  major  subgroups  depending  on  the 
pathogenic  mechanism:  thrombotic,  embolic  and 
hemodynamic  stroke.  This  classification  is  based  on 
results provided by imaging studies, and although there 
can be overlap between the groups, the classification is 
still relevant for prevention and management purposes.
The first major clinical classification was introduced in 
1991  with  the  Oxford  Community  Stroke  Project  [10], 
which was followed by a more widely accepted one in 
1993. This was developed for the Trial of Org10172 in 
Acute Ischemic Stroke (TOAST) [11] and was based on 
the  most  common  pathophysiological  mechanisms 
involved  in  the  development  of  stroke  (Table  1).  The 
system  comprises  five  subgroups:  (1)  the  large­vessel 
atherosclerotic type, in which patients have cortical or 
cerebellar lesions and/or brainstem infarcts or subcortical 
hemispheric infarcts greater than 1.5 cm in diameter on 
magnetic  resonance  imaging  (MRI),  with  or  without 
cerebral cortical impairment or brainstem or cerebellar 
dysfunction;  (2)  the  small­vessel  occlusion  type,  which 
includes  patients  with  one  or  more  subcortical  hemi­
spheric or brainstem infarcts with a diameter less than 
1.5 cm on MRI, with one of the features of the traditional 
clinical  lacunar  syndrome  (a  constellation  of  clinical 
symptoms  (pure  motor  stroke,  pure  sensory  stroke, 
sensorimotor stroke and ataxic hemiparesis), and signs at 
the time of maximum deficit following a single cerebro­
vascular event) and without cerebral cortical dysfunction; 
(3) the cardioembolic subtype, which comprises patients 
with  arterial  occlusions  presumably  resulting  from  an 
embolus arising in the heart; (4) stroke with other deter­
mined etiology, which includes patients with rare causes 
of stroke, such as hematological disorders, non­athero­
sclerotic vasculopathies and hypercoagulability (increase 
in  coagulability);  and  (5)  stroke  with  unidentified 
etiology,  in  which  the  cause  of  stroke  cannot  be 
determined [11].
Stroke  is  a  multifactorial  disease.  Environmental 
factors can have a crucial role in the development of the 
disease. Several risk factors have been identified, which 
were  categorized  as  potentially  modifiable  and  non­
modifiable [12­14]. Age, gender and previous history of 
stroke  are  some  of  the  non­modifiable  risk  factors, 
whereas hypertension, diabetes mellitus, obesity, elevated 
triglyceride and cholesterol levels, smoking, high alcohol 
consumption and presence of cardiovascular events are 
some modifiable risk factors.
Recently,  the  potential  role  for  several  naturally 
occurring genomic variants has come into the focus of 
epidemiological studies. Significant progress has already 
been  made  in  the  identification  of  genetic  variants  for 
stroke  and  other  cerebral  and  cardiovascular  disorders 
[15­19], and research into these variants provides new 
insights into the pathogenesis of these conditions.
Rare  forms  of  ischemic  stroke  appear  as  prime 
manifestations of multisystemic disorders, such as cerebral 
arteriopathy with subcortical infarcts and leuko  encepha­
lo  pathy (CADASIL), Fabry’s disease, Marfan syndrome, 
and  ‘mitochondrial  myopathy,  encephalopathy,  lactic 
acidosis  and  stroke­like  episodes’  (MELAS  syndrome). 
These conditions show typically Mendelian or maternal 
inheritance and result from defects in single genes, such 
as  NOTCH3,  α­galactosidase  (GLA),  fibrillin­1  (FBN1) 
and  mitochondrial  tRNA­encoding  genes,  respectively 
[20­24].  Numerous  studies  have  revealed  single­gene 
disorders [25­32]; the discussion of these conditions is 
outside the scope of this article.
Three periods in stroke susceptibility research
Classic genetic risk factors for stroke
The first studies into the genetic background of stroke 
involved the examination of single genetic variants that 
might  be  involved  in  pathogenic  mechanisms  of  this 
condition.  This  period  (approximately  1985  to  1995), 
which can be regarded as the first wave of stroke genetic 
research, was also the beginning of susceptibility allele 
research  for  numerous  other  multifactorial  diseases, 
including  ischemic  heart  disease,  type  2  diabetes  and 
metabolic  syndrome.  Several  polymorphisms  of  genes 
influencing  hemostasis  and  homocysteine  metabolism 
and  genes  encoding  enzymes  involved  in  the  renin­
angiotensin  system  and  nitric  oxide  (NO)  production 
were  identified  as  risk  factors  for  ischemic  stroke 
(Tables 2 and 3).
Disturbances in the balance of hemostasis can lead to 
increased  aggregation  of  blood  platelets  and  thrombus 
formation,  which  may  result  from  defects  in  genes 
encoding components of the coagulation cascade, such as 
factors  II,  V,  XIII  and  fibrinogen,  promoting  the 
Table 1. Classification of stroke subtypes from TOAST [12]
Subtype  Classification
1  Large-artery atherosclerosis (embolus/thrombosis)
2  Small-vessel occlusion (lacune)
3  Cardioembolism (high-risk/medium-risk)
4  Stroke of other determined etiology
5  Stroke of undetermined etiology
    (a) Two or more causes identified 
    (b) Negative evaluation
    (c) Incomplete evaluation
The classification of subtypes 1 to 4 includes possible or probable cases 
according to the results of ancillary studies as well as certain diagnoses.
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phenotypes. Activated factor V acts as a cofactor for the 
conversion  of  prothrombin  to  thrombin.  Bertina  and 
coworkers  [33]  first  identified  a  c.1691G>A  transition 
(p.Arg506Gln) in the F5 gene in a family with thrombo­
philia  in  1994.  The  c.1691G>A  alteration  (called  the 
Leiden variant) has been reported to be associated with 
resistance to degradation by activated protein C. Since 
then,  numerous  studies  have  examined  this  variant  in 
several conditions that correlate with thrombo  embolism, 
but  the  results  were  inconsistent  regarding  the  patho­
logical role of this alteration [34­37]. According to the 
results  of  a  large­scale  epidemiological  assessment, 
carriage of the 1691A allele was not associated with an 
increased  risk  of  stroke  [38].  However,  a  statistically 
significant association was found between the presence 
of  the  c.1691G>A  transition  and  ischemic  stroke  in  a 
meta­analysis  [39].  We  [40]  found  that  the  c.1691G>A 
alteration does not confer risk for stroke alone, but in 
combination  with  other  unfavorable  factors,  such  as 
hypertension  or  diabetes  mellitus,  it  can  increase  the 
relative risk of ischemic stroke.
The  most  extensively  studied  alteration  of  the  pro­
thrombin (factor II) gene is c.20210G>A, which was first 
described  in  1996  [41].  This  sequence  variation  is 
associated  with  elevated  prothrombin  levels.  Several 
studies  found  a  statistically  significant  association 
between ischemic stroke and this substitution [42,43]; the 
data of a meta­analysis also suggested that the c.20210G>A 
variant is a risk factor for ischemic stroke [39].
The p.Val34Leu substitution in factor XIII has also been 
suggested as a risk factor, but its role remains ambiguous 
according to the findings of association studies [44,45]. A 
meta­analysis  by  Casas  and  colleagues  [39]  suggested 
that the p.Val34Leu variant does not confer an increased 
risk for development of stroke.
The  c.455G>A  alteration  of  the  fibrinogen­encoding 
gene  has  been  found  to  occur  more  frequently  in 
homozygous  form  in  patients  with  large­vessel  stroke 
[46]. Carrying the rare allele causes elevated fibrinogen 
levels, which confers susceptibility to ischemic stroke by 
prothrombotic mechanisms. A similar relationship was 
found for other variants of the fibrinogen gene, but only 
in female patients [47].
The renin­angiotensin system regulates blood pressure 
and water balance. Renin, the key protease of the cascade, 
is secreted from the kidneys and cleaves angiotensinogen 
to  form  angiotensin  I.  This  intermediate  form  is  then 
Table 2. Genes and their polymorphisms associated with ischemic stroke in GWASs
System  Gene  Polymorphism  References
Hemostasis  Factor II (prothrombin) (+176930)  c.20210G>A  [39,41-43]
  Factor V (Leiden) (*612309)  p.Arg506Gln  [33-40]
  Factor XIII (+134570)  p.Val34Leu  [39,44,45]
Renin-angiotensin system  ACE (+106180)   Insertion/deletion  [40,48-51]
  AT1R (*106165)  c.1166A>C  [52-55]
Nitric-oxide-synthase system  eNOS (+163729)  p.Glu298Asp  [56-58]
Homocysteine metabolism  MTHFR (*607093)  c.677C>T and c.1298A>C  [43,59-61]
Lipid metabolism  APOE (+107741)  ε4, ε3, ε2  [40,46,62-66]
ACE, angiotensin converting enzyme; APOE, apolipoprotein E; AT1R, angiotensin-receptor; eNOS, endothelial nitric oxide synthase; MTHFR, 
5,10-methylenetetrahydrofolate reductase.
Table 3. Functional SNPs associated with ischemic stroke
System  Gene  Polymorphism  References
Lipid metabolism  APOA5 (*606368)  g.-1131T>C, c.1259T>C, c.56C>G, c.IVS3+476G>A  [82-88]
  APOCIII (*107720)  g.-2854T>G, g.-455C>T, g.-482C>T, c.3238C>G  [73-76]
  LPL (*609708)  p.Asn291Ser  [92-95]
  GCKR (*600842)  c.1337C>T  [104]
  MLXIPL (*605678)  rs17145738, rs3812316  [105]
  GALNT (*602274)  rs4846914  [104]
Signal transduction  PDE4D (*600129)  Six SNPs, haplotypes  [96-100]
Inflammation  ALOX5AP (*603700)  Seven SNPs, haplotypes  [97,100-103]
ALOX5AP, arachidonate 5-lipoxygenase-activating protein; APOA5, apolipoprotein A5; APOCIII, apolipoprotein CIII; LPL, lipoprotein lipase; PDE4D, phosphodiesterase 
4D.
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enzyme (ACE). The ACE gene, located on chromosome 
17, is one of the most intensively studied candidate genes 
associated with ischemic stroke. Cambien and colleagues 
[48]  first  described  the  insertion/deletion  (indel)  poly­
morphism of the gene in myocardial infarction. Six years 
later,  a  meta­analysis  reported  a  significant  positive 
association  between  the  deletion  polymorphism  of  the 
ACE gene and ischemic stroke [49]. The results of a large, 
prospective study indicate that the ACE indel polymor­
phism is not associated with subsequent risk of stroke 
[50]. In a Hungarian population we have found the ACE 
D/D variants (homozygous carriers of the deletion) to be 
associated with risk for development of stroke [40,51]. 
Subsequent studies have mostly investigated variants of 
the gene encoding angiotensin II receptor type I (AT1R 
c.1166A>C). AT1R has multiple effects, both cardiac and 
systemic, mediating vasoconstriction, cellular hyper  trophy 
and catecholamine release. In a Caucasian population a 
weak association was found between carrying the AT1R 
1166C allelic variant and stroke [52,53]. According to our 
results [54], the 1166C allelic variant is associated with 
susceptibility to the disease among hypertensive smokers. 
We  found  co­occurrence  of  ACE  indel  and  AT1R 
c.1166A>C  variants  to  confer  risk  for  small­vessel 
occlusion  type  stroke  in  a  Hungarian  population  [55]. 
Several  studies  have  investigated  ACE  indel  poly­
morphisms in association with numerous conditions, and 
they  are  believed  to  contribute  to  the  development  of 
atherosclerotic  mechanisms,  but  their  role  remains 
controversial.
The NO synthase system is an important regulator of 
the  integrity  and  growth  of  the  vascular  endothelium 
and  is  responsible  for  the  maintenance  of  normal 
endothelial  function.  The  endothelial  nitric  oxide 
synthase  (eNOS)  enzyme  converts  l­arginine  to l­
citrulline, generating NO in the arteries, and has a role 
in  vasodilation.  Under  pathological  conditions,  cells 
produce superoxide instead of NO, which can initiate the 
atherosclerotic process. In 1996, Wang and colleagues 
[56] first identified a functional variant (eNOS4a/b) of 
the  eNOS  gene  in  association  with  coronary  artery 
disease. Since then, several reports have studied variants 
in  eNOS  in  relation  to  ischemic  stroke.  Howard  and 
colleagues  [57]  found  that  a  promoter  region 
polymorphism (­786T>C) of eNOS is associated with 
ischemic stroke susceptibility in young black women. 
Another single­nucleotide poly  morphism (SNP) in 
this gene (c.894G>T) has been shown not to be a 
susceptibility  factor  for  ischemic  stroke;  however, 
co­occurrence with other SNPs, such as ACE D/D 
or  the  c.677C>T  in  the  5,10­methylenetetra­
hydrofolate  reductase  (MTHFR)  gene,  could 
increase stroke risk [58].
Hyperhomocysteinemia  caused  by  pathological 
homocysteine  metabolism  has  been  associated  with 
increased  risk  for  several  cardio­  and  cerebrovascular 
events.  Elevated  homocysteine  levels  can  result  from 
reduction  or  complete  absence  of  MTHFR  enzyme 
activity,  which  catalyzes  the  methylation  of  homo­
cysteine.  Variants  in  the  MTHFR  gene  (c.677C>T  or 
c.1298A>C) can lead to deficiencies in enzyme activity. 
The c.677C>T alteration was found to be an important 
risk  factor  for  cerebral  events.  Examination  of  these 
polymorphisms revealed no association between carriage 
of the 677T or 1298C alleles and development of stroke 
[43,59]. However, we [60] reported that co­occurrence of 
these two alleles confers susceptibility to ischemic stroke, 
in both heterozygous and homozygous carriers. A case­
control  study  [61]  demonstrated  that  the  677T  allelic 
variant is more prevalent in ischemic stroke patients in 
co­occurrence  with  the  AT1R  c.1166A>C  variant,  and 
together they confer increased risk for stroke.
Apolipoprotein  E,  the  main  apoprotein  in  the 
lipoprotein­transporting chylomicron particles, serves as 
a ligand for cellular receptors on liver and peripheral cells 
and interacts with proteoglycans on the endothelium to 
guide lipoproteins to lipases. The APOE gene, located on 
chromosome 19, is polymorphic, with three co­dominant 
alleles, ε2, ε3 and ε4, defining six genotypes [62]. Carriers 
of  the  ε2  alleles  have  lower  total  and  low­density 
lipoprotein (LDL)­cholesterol levels and elevated trigly­
ceride levels. Carriers of the ε4 allele have higher levels of 
both total and LDL­cholesterol than ε3/ε3 homozygotes 
[63].  Multiple  studies  have  shown  that  APOE  is  an 
important  predicting  factor  for  the  development  of 
ischemic  stroke  [46,64­66].  We  [40]  observed  that  the 
APOE  ε4  allele  alone  represents  a  minor  genetic  risk 
factor for ischemic stroke. However, the co­occurrence of 
the APOE ε4 allele and traditional risk factors, such as 
hypertension,  diabetes  mellitus,  smoking  and  alcohol 
consumption, results in a considerably elevated risk for 
ischemic stroke.
Further search for functional SNPs in stroke
In the second period of stroke research (approximately 
1995 to 2007), the identification of functional variants as 
possible susceptibility genes increased rapidly. Increased 
concentrations of plasma lipids, triglyceride and choles­
terol levels were found to be independent risk factors for 
cardio­  and  cerebrovascular  disorders  [67­69].  Plasma 
triglyceride levels are determined by numerous genes and 
their interactions with the environment. The search for 
genetic variations affecting plasma triglyceride concen­
trations  is  still  ongoing;  several  loci  identified  so  far 
include  the  apolipoprotein  genes  APOAI,  APOCIII, 
APOAIV, and APOA5 and the lipoprotein lipase (LPL) 
gene [66,70].
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the  plasma  transport  of  lipids.  They  can  activate  or 
inhibit  enzymes  involved  in  lipoprotein  metabolism  or 
serve as signals for receptors in the liver or other cells. 
Genetic variations influencing their protein structure or 
synthesis  may  affect  lipid  metabolism,  resulting  in 
progression  to  cardio­  and  cerebrovascular  disorders. 
The  currently  known  apolipoproteins  are  APOAI, 
APOAII,  APOAIV,  APOA5,  APOB48,  APOB100, 
APOCI­APOCIII and APOE. The APOAI, APOCIII and 
APOAIV genes on chromosome 11 are so far the most 
intensively studied genes [71]. APOCIII encodes a protein 
of 79 amino acids that is synthesized in the liver and the 
intestines  and  is  an  essential  constituent  of  circulating 
particles,  such  as  very  low  density  lipoprotein  (VLDL) 
and  chylomicrons  [72].  Several  polymorphisms  of 
APOCIII have been associated with hypertriglyceridemia 
[73].  Carriers  of  the  G  allele  of  the  c.3238C>G  poly­
morphism in the APOCIII 3’ untranslated region (UTR) 
were  reported  to  have  higher  plasma  triglyceride 
concentrations,  as  were  individuals  with  two  minor 
alleles (­482C>T and ­455T>C) of the APOCIII promoter 
[74,75].  Because  APOCIII  inhibits  the  hydrolysis  of 
triglyceride­rich  particles  by  lipoprotein  lipase,  its 
overexpression leads to hypertriglyceridemia [72]. Only a 
few studies have explored the role of the APOCIII gene 
g.8017G>C (rs5128) polymorphism in the development 
of  ischemic  stroke.  Aalto­Setälä  and  colleagues  [76] 
found  a  negative  association  between  this  APOCIII 
polymorphism and ischemic stroke.
The APOA5 gene is located near the APOAI-APOCIII-
APOAIV cluster and encodes a 366 amino acid protein 
[77]. The mature APOA5 protein is synthesized in the 
liver and secreted into the plasma [78]. Evidence supports 
a  central  regulatory  role  for  APOA5  in  triglyceride 
metabolism  through  the  inhibition  of  hepatic  VLDL 
production  or  by  guiding  VLDL  and  chylomicrons  to 
proteoglycan­bound lipoprotein lipase [79,80]. Further­
more,  APOA5  has  been  described  to  indepen  dently 
influence  plasma  triglyceride  levels  in  an  opposing 
manner to APOCIII [81]. Around 40 polymorphisms of 
the APOA5 gene have been identified since the discovery 
of the gene [82­84]. These natural variants may alter the 
function  of  the  protein.  The  most  common  variants, 
­1131T>C (rs662799) in the promoter region, g.1259T>C 
(rs2266788) in the 3’ UTR region, c.56C>G (rs3135506, 
resulting in a serine­to­tryptophan amino acid change in 
the  signal  peptide),  and  intronic  g.IVS3+476G>A 
(rs2072560;) have been repeatedly linked with elevated 
triglyceride  levels  [77,84,85].  Some  of  them  have  also 
been  found  to  be  independent  risk  factors  for  several 
conditions  of  triglyceride  metabolism.  The  carriage  of 
­1131C  and  g.IVS3+476A  mutant  alleles  have  been 
established  to  confer  increased  risk  for  all  subtypes  of 
ischemic  stroke  [86,87].  In  Hungarian  individuals,  we 
found  the  56G  allele  to  be  associated  only  with  large­
vessel stroke [88], but found the 1259C variant not to be 
associated with an increased risk for the disease [87]. The 
most  common  SNPs  of  APOA5  are  in  strong  linkage 
disequilibrium and constitute haplotype variants desig­
na  ted  by  asterisks  (APOA5*2,  *3,  *4  and  *5).  Among 
these, APOA5*2 was ascertained to be a risk factor for 
ischemic stroke. In any case, APOA5 is an example of 
shared susceptibility: we have found this naturally occur­
ring variant and haplotypes to also confer susceptibility 
to other diseases, such as metabolic syndrome [89­91].
LPL is another important enzyme for triglyceride meta­
bolism; it catalyzes the hydrolysis of chylomicron­ and 
VLDL­associated triglycerides with the cofactor APOCII 
[92].  Approximately  100  polymorphisms  have  been 
described in the LPL gene. Most of these variants can 
lead to decreased LPL activity, which increases plasma 
triglyceride  levels  and  the  risk  of  atherosclerosis  [93]. 
Huang et al. [94] found that the p.Asn291Ser alteration 
has a significant influence on serum levels of triglycerides, 
but this polymorphism does not contribute greatly to the 
overall risk of ischemic stroke. The results of a subsequent 
study [95] suggest that the p.Asn291Ser substitution is 
not associated with ischemic stroke in men but it possibly 
confers a twofold risk in women.
cAMP­specific  3’,5’­cyclic  phosphodiesterase  4D 
(PDE4D)  is  an  important  regulator  of  proliferation  of 
smooth muscle cells and macrophages, acting by degrad­
ing  a  key  signaling  molecule,  cAMP.  Defects  in  the 
protein result in the accumulation of cAMP in various 
cell types, such as monocytes and T lymphocytes. It can 
inhibit  immune  functions,  such  as  proliferation  and 
cytokine secretion, which can lead to atherosclerosis and 
plaque  instability.  The  gene  located  on  chromosome  5 
encoding PDE4D was identified by Gretarsdottir et al. in 
2003 [96]. Among the 260 SNPs examined by the authors 
[96], six have been found to be associated with stroke. 
Haplotype  analyses  have  also  shown  significant  corre­
lation between certain haplotypes and ischemic stroke. 
Sixteen replication studies have since been published on 
the association between SNPs in PDE4D and ischemic 
stroke  in  different  populations,  with  divergent  results. 
Some  of  them  confirmed  the  previously  described 
positive  association  [97,98],  whereas  others  dispute  an 
association [99,100]. The inconsistent results may origi­
nate  from  differences  between  the  population  samples 
analyzed.
The  gene  encoding  arachidonate  5­lipoxygenase­
activating protein (ALOX5AP) has also been the focus of 
association  studies.  ALOX5AP  is  a  proinflammatory 
mediator  that  is  implicated  in  the  pathogenesis  and 
progression  of  atherosclerosis.  Several  polymorphisms 
and  haplotypes  were  identified  in  ALOX5AP  that  have 
Maasz and Melegh Genome Medicine 2010, 2:64 
http://genomemedicine.com/content/2/9/64
Page 5 of 11been  shown  to  confer  increased  risk  for  stroke  in  an 
Icelandic population [101]. This result was confirmed in 
German  and  Scottish  populations  [102,103].  However, 
some  studies  [97]  found  no  association  between  the 
presence  of  polymorphisms  in  ALOX5AP  and  clinical 
pheno  types.  Further  investigation  into  the  functional 
consequences of these variants is under way.
Before genome­wide association studies (GWASs) were 
used to study stroke, they were applied to other common 
diseases, such as Parkinson’s disease, myocardial infarc­
tion, inflammatory bowel disease, and even rela  tively rare 
conditions,  such  as  macular  degeneration.  However, 
variants  discovered  in  GWASs  focusing  on  alleles 
involved  in  triglyceride  metabolism,  such  as  a  variant 
(rs780094) of the glucokinase regulatory protein (GCKR), 
which  is  associated  with  increased  triglyceride  levels, 
were also investigated in relation to stroke [66,70]. The 
GCKR gene, located on chromosome 2, encodes a protein 
of 625 amino acids that inhibits glucokinase in liver and 
pancreatic cells by binding the enzyme non­covalently to 
form an inactive complex. Járomi et al. [104] investigated 
the  GCKR  c.1337C>T  (rs1260326)  variant  in  a  case­
control study on a stratified stroke population; no asso­
cia  tion  could  be  detected  of  GCKR  alleles  with 
triglyceride levels or with the susceptibility to stroke.
GWAS analysis has also identified SNPs localized at the 
GALNT2  and  MLXIPL­TBL2  loci  as  being  associated 
with increased triglyceride levels [66,70]. The rs4846914 
variant is an intronic variant of the UDP­N­acetyl­α­d­
galactosamine:polypeptide  N­acetylgalactosaminyl  trans­
ferase  2  (GALNT2)  gene,  and  its  minor  G  allele  was 
reported  to  associate  with  higher  triglyceride  concen­
trations. The GALNT2 gene is responsible for the transfer 
of an N­acetyl galactosamine to the hydroxyl group of a 
serine or threonine residue in the first step of O­linked 
oligosaccharide  biosynthesis.  Our  Hungarian  case­
control  study  [104]  evaluated  the  association  of  the 
GALNT2 rs4846914 variant with triglyceride levels and 
explored their possible contribution to the development 
of ischemic stroke. No positive association was detected 
either with triglyceride levels or with susceptibility to the 
disease [104].
The  major  alleles  of  the  rs17145738  and  rs3812316 
variants  within  the  MLXIPL­TBL2  region  have  been 
found to be associated with increased triglyceride levels 
[66,70].  MLXIPL  encodes  a  transcription  factor,  MXL 
interacting protein­like, which has a role in the activation 
of carbohydrate response element motifs in the promoter 
region of genes involved in lipogenesis and triglyceride 
synthesis and regulates lipogenesis and glucose utiliza­
tion  in  the  liver.  TBL2  encodes  transducin  β­like  2 
protein, which is thought to be involved in intracellular 
signaling. We [105] examined the effect of rs17145738 
and  rs3812316  variants  on  triglyceride  levels  and  on 
stroke  susceptibility.  The  results  showed  that  the 
presence of these variants did not result in elevated 
triglyceride  levels  and  did  not  confer  risk  for 
ischemic stroke.
Genome-wide association studies in ischemic stroke
The  first  GWAS  directly  focused  on  ischemic  stroke 
patients was published in 2007 [106] (see Table 4 for a 
summary of GWASs reported so far in association with 
ischemic stroke). Matarín and colleagues [106] analyzed 
278 ischemic stroke patients and 275 controls for more 
than  408,000  unique  SNPs  using  Illumina  Infinium 
Human­1  and  HumanHap300  assays.  The  ischemic 
stroke subtypes were allocated according to the specified 
TOAST  classification.  The  results  showed  hundreds  of 
nominally  statistically  significant  associated  markers, 
among  them  the  most  notable  candidate  loci  are 
inositol(myo)­1(or  4)­monophosphatase  2  (IMPA2)  on 
chromosome 18, which is involved in the phosphatidyl­
inositol  signaling  pathway,  and  Kv  channel  interacting 
protein  4  (KCNIP4)  on  chromosome  4  and  potassium 
channel  K17  (KCNK17)  on  chromosome  6,  which  are 
involved in potassium transport [106].
In 2008, Gretarsdottir and colleagues [107] described 
the results of a well powered GWAS with 1,661 ischemic 
stroke patients from the Icelandic population, classified 
according to TOAST, and 10,815 controls. The authors 
used  Illumina  Infinium  Human­1  and  HumanHap300 
chips for genome­wide genotyping of more than 310,000 
SNPs,  from  which  120  were  selected  for  replication. 
Among  those,  rs2200733  and  rs10033464  in  the  gene 
encoding the transcriptional activator PITX on chromo­
some 4q25 were found to be significantly associated with 
the development of ischemic stroke, especially for stroke 
due to cardioembolism (cardiogenic stroke) [107]. Some 
variants  identified  in  the  gene  have  previously  been 
associated  with  Axenfeld­Rieger  syndrome,  which  is  a 
rare  autosomal  dominant,  genetically  heterogeneous 
disorder characterized by abnormal development of the 
anterior segment of the eye resulting in ocular changes 
and  accompanied  by  systemic  features,  such  as 
craniofacial dysmorphism, dental anomalies and cardiac 
malformations [108,109].
A Japanese GWAS [110], which included 6,341 partici­
pants (992 ischemic stroke patients and 5,349 controls), 
analyzed more than 520,000 SNPs using the GeneChip 
Human  Mapping  500K  Array  from  Affymetrix  and 
selected  100  SNPs  for  replication.  This  study  [110] 
reported polymorphisms in the cadherin EGF LAG seven­
pass G­type receptor 1 (CELSR1) gene on chromosome 
22 as susceptibility factors for ischemic stroke. CELSR1 
encodes a transmembrane G­protein­coupled receptor.
Ikram et al. [111] carried out a combined analysis of 
GWAS  data  generated  from  four  large  cohorts 
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Cardiovascular  Health  Study).  The  cohorts  include 
19,602 participants, of whom 1,164 were patients having 
suffered ischemic stroke. The genotyping was performed 
with  different  platforms  (Affymetrix  GeneChip  SNP 
Array 6.0, GeneChip Human Mapping 500K Array and 
50K  Human  Gene  Focused  Panel;  Illumina 
HumanCNV370­Duo and Infinium HumanHap550 3.0). 
Two of the analyzed SNPs, rs11833579 and rs12415791 
on  chromosome  12  near  the  nerve  injury­induced 
protein  2  (NINJ2)  and  WNK  lysine  deficient  protein 
kinase 1 (WNK1) genes, were confirmed in the replica­
tion study, which revealed a positive association between 
carrying minor alleles and ischemic stroke, in particular 
the atherothrombotic stroke subtype [111].
Despite  their  huge  power  and  impact,  GWASs  also 
have limitations. In a few cases [110], the studies involved 
a single population. Validation of the findings in different 
ethnic  groups  will  be  required.  In  certain  replication 
studies [106], the number of participants was too small 
and  the  functional  relevance  of  the  identified  poly­
morphisms remains unclear. Further genotyping as well 
as  detailed  functional  and  epidemiological  studies  in 
larger populations are therefore required to identify the 
exact  role  and  associations  of  these  genes  and  gene 
variants in the development of ischemic stroke.
Concluding remarks
Significant progress has been seen in the field of stroke 
susceptibility  genetics  over  the  past  one  and  a  half 
decades; however, research intensity has been moderate 
in comparison with other multifactorial diseases, such as 
diabetes, metabolic syndrome or ischemic heart diseases. 
It has become clear that stroke shows a complex pheno­
type and, as a result, a careful stratification of the patients 
is  essential,  as  the  genetic  etiology  can  differ  strongly 
between the subtypes. An imbalance in research intensity 
can  also  be  observed  for  the  different  stroke  groups: 
causative  genes  are  still  to  be  discovered  for  some 
Mendelian forms, whereas in the polygenic groups the 
majority of efforts are mainly restricted to the small­ and 
large­vessel associated stroke variants, with less frequent 
rare variants receiving little attention. Thus, although the 
available biobanks have been valuable for moving small­ 
and  large­vessel  associated  stroke  pathology  research 
forwards,  they  should  be  strengthened  with  additional 
samples from the less frequent stroke types. This may not 
be a simple task, given the small incidence rates of these 
rare variants.
As has occurred for other diseases, the recent GWAS 
area has opened new perspectives for susceptibility gene 
research in relation to stroke. It is now clear that some 
susceptibility alleles can be shared: the same allele can 
confer susceptibility to stroke, ischemic heart diseases or 
even  metabolic  syndrome.  Some  susceptibility  factors 
that are associated with clinical traits can themselves also 
be  risk  factors  for  stroke:  thus,  alleles  associated  with 
increased  triglyceride  levels  can  also  be  susceptibility 
factors  for  stroke.  The  possible  association  between 
triglyceride levels and stroke is an old question; future 
association  studies  will  help  us  understand  which 
naturally  occurring  genetic  variants  associate  with 
increased triglycerides alone without stroke and which 
variants  also  associate  with  cerebral  pathology.  In  a 
broader  context,  better  knowledge  about  different 
metabolic  and  biochemical  parameters  in  the  healthy 
population will also help us to understand their potential 
role in the development of stroke [112].
Although susceptibility allele tests are offered on the 
palette of some direct­to­consumer companies, we have 
to  keep  in  mind  that  current  evidence  does  not  yet 
support their use in clinical practice [113­118] given that 
Table 4. Genome-wide association studies on stroke 
        Number 
      Number  of SNPs                               Positive association 
    Sample size  of SNPs  examined in   
Population  Sample size  in replication  examined  replication  Gene  Variant  Platform  References
Caucasian  1164 cases,   3656 cases,   2,194,468  2  Near NINJ2  rs11833579,   Affymetrix,   [111]
  18438 controls  3,613 controls      and WNK1  rs12425791  Illumina 
Japanese  992 cases,   705 cases,   520,000  100  CELSR1   rs6007897,   Affymetrix  [110]
  5349 controls  3,426 controls      (*604523)  rs4044210   
Caucasian  1,661 cases,   2,224 cases,   310,881  120  Near PITX2   rs2200733,   Illumina  [107]
  10,815 controls  2,583 controls      (*601542)  rs10033464   
    or 2,327 cases,  
    16,760 controls
US  249 cases,   -  408,000  -  IMPA2 (*605922), )  rs7506045  Illumina  [106]
  268 controls        KCNIP4 (*608182),      
          KCNK17 (*607370
CELSR1, cadherin EGF LAG seven-pass G-type receptor 1; IMPA2, inositol(myo)-1(or 4)-monophosphatase 2; KCNIP4, Kv channel interacting protein 4; KCNK17, 
potassium channel, subfamily K, member 17; NINJ2, Nerve injury-induced protein 2; PITX2, paired-like homeodomain 2.
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Page 7 of 11the predictive value of these test results is still limited. 
The  rapid  spread  of  exome  sequencing  and  whole­
genome sequencing techniques will probably help us to 
identify novel genes in stroke types that have a Mendelian 
monogenic origin, even for rare stroke types, rather than 
helping to understand the complex pathology associated 
with polygenic types of stroke.
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